We observed that most of the genes more transcriptionally altered by sorafenib administration, according to the results we obtained in sorafenib-treated tumors, such as PYCARD, CASP1, NOD2, FADD, or NFKBIB were associated with unfavorable outcomes for HCC patients (Figure 2 and enhanced images available in Supplemental Figures S1 and S2). This evidence concerns the gene NOD2 and hepatocellular carcinoma.